SEATTLE — Sept. 3, 2024 — Fred Hutch Cancer Center added a new member to its board of directors: Michelle Seitz, founder and CEO of MeydenVest Partners and former chair and CEO of Russell Investments.
Seitz joined Fred Hutch’s board effective Sept. 1. She currently serves on the boards of MSCI Inc., Sana Biotechnology and Indiana University’s Kelley School of Business, and is an advisor to University of Chicago’s Leadership & Society Initiative.
“It’s an honor to join the Fred Hutch board and work with world class people who are wholly dedicated to saving people’s lives,” said Seitz. “Fred Hutch is on the cutting edge of cancer research and clinical care, and I’m thrilled to support this work and help drive the organization toward its next advancements in treatment and cures.”
With over three decades as both a CEO and investor, Seitz brings deep experience in the financial sector. She founded MeydenVest Partners in 2022 with the goal of ensuring that businesses solving important societal issues have access to strategic advice and patient capital. At the companies she has led, a hallmark of her approach was leveraging her platform and voice to push for systemic change to improve peoples’ financial security.
Before joining Russell Investments, Michelle was CEO of William Blair Investment Management and served on William Blair’s corporate board of directors. She is also a former trustee on the Financial Accounting Foundation, former board member on the Washington Roundtable and former co-chair of Challenge Seattle.
“Michelle brings tremendous financial and leadership expertise to our board of directors and has a passion for solving some of the biggest challenges in our society, including cancer,” said Dr. Thomas J. Lynch, president and director of Fred Hutch and holder of the Raisbeck Endowed Chair. “We’re honored to have her join the Fred Hutch board and help us advance our mission.”
Seitz has been recognized on Barron’s list of "The Most Influential Women in U.S. Finance" and American Banker’s list of the "Most Powerful Women in Finance."
##
Media Contact:
Kat Wynn
kwynn@fredhutch.org
Fred Hutch Cancer Center
Fred Hutch Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.
Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program.